Építés alatt – nem éles oldal
Belépés
Visszavonva1. fázis

A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer

A legfontosabb adatok

Ki végzi
Codagenix, Inc
Hol
Boston és Canton (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Visszavonva
Fázis
1. fázis
Kezdés
2023. jan. 15.
Befejezés
2025. jan. 30.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • CodaLytic
A regiszteradat frissítve
2023. október 18.
Miért állt le
Due to funding decision by the sponsor

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 20 feltétel megnézéseKevesebb

Ki vehet részt

  • Women or men with metastatic or inoperable, histologically confirmed breast cancer
  • Has no alternative treatment of proven benefit available or has refused treatment
  • Expected survival ≥ 3 months
  • At least 2 measurable lesions according to RECIST 1.1, without contraindication for repeated injections and core needle biopsies
  • Adequate organ function
  • Eastern Cooperative Oncology Group performance status of 0 to 2
  • Negative pregnancy test, if female
  • Agreement to practice a highly effective method of contraception
  • Agreement to no sperm donation through 28 days, if male
  • Willing to provide consent to perform study procedures

Ki nem vehet részt

  • Anticancer therapy within 3 weeks of dosing
  • Presence of a concurrent malignancy for which the natural history or treatment has the potential to interfere with the safety or efficacy assessment of the Investigational Product
  • Immunodeficiency or use of therapies expected to impair the immune response within thirty (30) days of enrollment or during dosing
  • Ongoing toxicity > Grade 1 from prior treatment except those which are stable
  • Planned radiation to lesions targeted for assessment/injection within 60 days before first dose or any planned radiation during dosing period
  • Uncontrolled or severe cardiovascular disease
  • History of severe reaction (ie, anaphylaxis) to vaccination or immunotherapy
  • Any condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a participant's ability to give informed consent
  • Pregnant or lactating women
  • Known active central nervous system metastases (with some exceptions)

Helyszínek itt: Egyesült Államok

  • Dana-Farber Cancer InstituteBoston, Egyesült Államok
  • Gabrail Cancer CenterCanton, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast cancer.

A teljes eredeti leírásKevesebb

The main questions it aims to answer are:

* How safe is CodaLytic when administered in escalating dosing groups into targeted lesions? * What is the impact of CodaLytic on lesion response and disease progression?

Eligible participants will be enrolled into four (4) escalating dose groups and treated with Codalytic through injection into a selected lesion(s) over twelve (12) weeks and then followed for up to one (1) year after the first dose. A safety committee will review the safety profile of each dosing group before the next dose-escalation.

Study procedures will include physical examinations, injection site assessments, biopsies, imaging, and collection of blood/urine to assess safety, the body's immune response, and efficacy.

A vizsgálat 4 csoportja

  • 10e7 PFU dose 3 injectionsA vizsgált kezelés

    10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)

    Kezelés: CodaLytic

  • 10e7 PFU dose 5 injectionsA vizsgált kezelés

    10e7 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)

    Kezelés: CodaLytic

  • 10e8 PFU dose 3 injectionsA vizsgált kezelés

    10e7 PFU CodaLytic administered intratumorally once every 4 weeks (3 doses total)

    Kezelés: CodaLytic

  • 10e8 PFU dose 5 injectionsA vizsgált kezelés

    10e8 PFU CodaLytic administered intratumorally once every 2 weeks (5 doses total)

    Kezelés: CodaLytic

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer
A regiszteradat frissítve
2023. október 18.